Cryoport, Inc. (CYRX) Stock Price & Analysis

Cryoport, Inc. (CYRX) is trading at USD 18.58, down 0.32% today, as of October 29, 2026 at 16:30 UTC (US market open; quotes may be delayed), according to Nexqual market data.

CYRX last closed at USD 18.64; today's session has ranged USD 18.31–18.69 on volume of 125,299 shares. Market capitalization is $941.06M, with a 52-week range of USD 7.61–18.88 (NCM). Source: Nexqual, retrieved October 29, 2026 at 16:34 UTC.

Also available as compact Markdown for AI agents: nexqual.com/CYRX.md

Key facts (CYRX)

• Last four reported quarters (through Jun 30, 2026): revenue $186M, net income -$37.4M (-20.1% margin), free cash flow -$20.0M (SEC filings).
• 1 of 80 tracked superinvestors hold CYRX (13F, Q2 2026): 0 new, 1 added, 0 reduced, 0 unchanged.
• Insider open-market sales, last ~7 months: 4 Form 4 filings, $4.1M; 3 not under a Rule 10b5-1 plan ($3.6M); 0 by opportunistic insiders, 2 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
• Analysts: Buy (mean 2.00 on a 1–5 scale) (9 analysts), mean target USD 19.78 (range 15–26).
• Total return with dividends: 1Y +101.1% vs S&P 500 +13.1%; 5Y -77.2% vs S&P 500 +79.1%.
• Next earnings: 2026-11-05, EPS estimate USD -0.17, revenue estimate $48.7M.

Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (CYRX)

Fiscal years end Dec. EPS is split-adjusted.

Valuation (price ÷ last four quarters, through Jun 30, 2026) (CYRX)

P/S 5.0x · EV/Sales 2.9x · P/B 1.9x · FCF yield -2.13% · Earnings yield -3.97% · Net cash $396M · EV $545M

P/E at fiscal year-ends: Dec 2025 6.1x.

Superinvestors (SEC 13F-HR, Q2 2026) (CYRX)

1 of 80 tracked investors hold CYRX. Each row is the investor's latest 13F; change is vs their prior-quarter share count.

Insider sales (SEC Form 4, open-market, last ~7 months) (CYRX)

1 of 4 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.

% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).

Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

Analysts (CYRX)

Consensus Buy (mean 2.00 on a 1–5 scale), 9 analysts; mean target USD 19.78 (low 15, high 26).

Rating changes, last 120 days:

Total return (dividends reinvested) (CYRX)

CYRX earnings history and stock reaction

EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).

CYRX recent SEC filings (last 120 days)

Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.

CYRX suppliers, customers and competitors (named in its 10-K)

Quoted from the company's 10-K filed Mar 5, 2026.

CYRX analyst estimates and revisions

Key Statistics (as of October 29, 2026 at 16:34 UTC)

Technical Analysis (CYRX)

Nexqual's technical model rates CYRX "BUY" based on 5 bullish and 1 bearish signals across 128 daily candles, as of October 29, 2026 at 16:34 UTC.

Analyst Ratings (CYRX)

Wall Street analysts rate CYRX "Buy" based on 9 analysts, with a mean price target of USD 19.78 (range USD 15–26), per Nexqual as of October 29, 2026 at 16:34 UTC.

Earnings (CYRX)

Recent Earnings History

Source: Nexqual, October 29, 2026 at 16:34 UTC.

Financials & Fundamentals (CYRX)

Source: Nexqual, October 29, 2026 at 16:34 UTC.

Financial Health Score (CYRX)

Nexqual rates Cryoport, Inc.'s overall financial health "Weak" across five dimensions, as of October 29, 2026 at 16:34 UTC.

Ownership (CYRX)

Source: Nexqual, October 29, 2026 at 16:34 UTC.

Leadership (CYRX)

Cryoport, Inc. is led by Jerrell W. Shelton, Chairman, President & CEO, per Nexqual as of October 29, 2026 at 16:34 UTC.

Major Backers & Investors (CYRX)

Notable institutional backers of Cryoport, Inc. include Cadian Capital Management, LP, Morgan Stanley, Millennium Management, according to Nexqual as of October 29, 2026 at 16:34 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, October 29, 2026 at 16:34 UTC.

From Cryoport, Inc.'s Latest SEC 10-K Filing (filed 2026-03-05)

Key Strengths & Strategy (as disclosed to the SEC)

• Our integrated temperature-controlled supply chain solutions combine advanced logistics, biostorage, kitting and labelling, clinical sample management, collection and cryopreservation services for cell therapies starting materials, cryogenic systems manufacturing, and an industry-leading informatics platform that integrates all our solutions.
• We operate a Global Supply Chain Center Network through which we provide our BioLogistics, BioStorage, BioServices, and Cryopreservation services, supporting the end-to-end requirements of the life sciences industry.
• Cryoport continues to expand the foundations for its fully integrated solutions through ongoing enhancements to the Cryoportal, broader deployment of its Smartpak® Condition Monitoring System and Tec4med IoT-based monitoring solutions, and deeper integration of quality systems such as Chain of Compliance.
• Patents provide some degree of protection for our proprietary technology.

Partnerships

• The divestiture and strategic partnership with DHL are expected to enhance our ability to develop our business, particularly in the Europe, the Middle East, and Africa (EMEA) and Asia-Pacific (APAC) regions, and to provide differentiated and high-value services aligned with our long-term growth strategy.
• We also entered into certain related agreements in connection with the transaction, including a master partnership agreement.

Legal & Regulatory Risks (Item 1A, quoted)

• Changes in trade policy, tariff and import/export regulations may have a material adverse effect on our business, financial condition and results of operations.
• We, along with our customers, are subject to various international governmental regulations. Compliance with or changes in such regulations may cause us to incur significant expenses, and if we fail to maintain satisfactory compliance with certain regulations, we may be forced to recall products and cease their manufacture and distribution, and we could be subject to civil or criminal penalties.
• We are subject to regulation by the FDA or certain similar foreign regulatory agencies, and failure to comply with such regulations could harm our reputation, business, financial condition and results of operations.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 29, 2026 at 16:34 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt